Bortezomib enhances G-CSF-induced hematopoietic stem cell mobilization by decreasing CXCL12 levels and increasing vascular permeability

Autologous hematopoietic stem cell transplantation (ASCT) with high-dose chemotherapy is a standard therapy for multiple myeloma [1-3] and relapsed non-Hodgkin's lymphoma [4-6]. For rapid hematopoietic recovery after ASCT, it is essential to collect and infuse a sufficient number of hematopoietic stem and progenitor cells (HSPCs). Administration of granulocyte colony-stimulating factor (G-CSF) induces HSPC mobilization from bone marrow (BM) to peripheral blood (PB). However, there are 5 –30% of patients, referred to as poor mobilizers, who are unable to collect adequate numbers of HSPCs by G-CSF [7, 8].

Source: Experimental Hematology - February 19, 2021 Category: Hematology Authors: Taichi Matsumoto, Yasushi Takamatsu, Hanae Moriyama, Kazuki Terada, Masayoshi Mori, Kazuhiko Ono, Keisuke Migita, Shuuji Hara Source Type: research